Example of an acute lymphoblastic leukaemia treatment programme in Brazil*
| Sensitivity analysis | |||
|---|---|---|---|
| 3% Discounting | 6% Discounting | 0% Discounting† | |
| Years of life lost without treatment | 35.90 | 20.26 | 67.14 |
| Years lived with disability without treatment | 0.02 | 0.02 | 0.02 |
| Years lived with disability during treatment | 0.14 | 0.14 | 0.18 |
| DALYs lost per untreated case, years | 35.92 | 20.28 | 67.20 |
| National DALYs with no treatment, years | 48 298.41 | 27 265.88 | 90 314.76 |
| National DALYs averted with treatment, years | 29 049.91 | 15 968.11 | 54 993.68 |
| Upper limit of cost effective, US$/case | $771 225 | $423 926 | $1 459 988 |
| Upper limit of very cost effective, US$/case | $257 075 | $141 309 | $486 663 |
*If results from the included sample study were replicated at the national level.
†No age weight was applied as well.
DALYs, disability-adjusted life years; YLD, years lived with disability.